Cellular signal transduction can be induced by TRAIL conjugated to microcapsules

Journal of Biomedical Materials Research - Part A

Volumn 100 A, Issue 10, 2012, Pages 2602-2611

  Wheatley, Margaret A ^a   Cochran, Michael C ^a   Eisenbrey, John R ^a   Oum, Kelleny L ^a  

^a DREXEL UNIVERSITY   (United States)

Author keywords

cellular signal transduction; microcapsule; proteasome inhibitors; surface modification; TRAIL; ultrasound contrast agents

Indexed keywords

CELLULAR SIGNAL TRANSDUCTION; MICROCAPSULES; PROTEASOME INHIBITORS; TRAIL; ULTRASOUND CONTRAST AGENT;

CELL CULTURE; FLOW CYTOMETRY; NANOPARTICLES; SIGNAL TRANSDUCTION; SURFACE TREATMENT; TUMORS; ULTRASONIC IMAGING; ULTRASONICS;

CELL DEATH;

BORTEZOMIB; ECHO CONTRAST MEDIUM; NANOPARTICLE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ECHOGRAPHY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MICROCAPSULE; OVARY CANCER; PARTICLE SIZE; SIGNAL TRANSDUCTION;

ANNEXIN A5; APOPTOSIS; BORONIC ACIDS; CAPSULES; CELL LINE, TUMOR; CONTRAST MEDIA; DOXORUBICIN; FLOW CYTOMETRY; HUMANS; LACTIC ACID; MELANOMA; MEMBRANES, ARTIFICIAL; PARTICLE SIZE; POLYMERS; PYRAZINES; SIGNAL TRANSDUCTION; STAINING AND LABELING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; ULTRASONICS;

EID: 84865624487     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34189     Document Type: Article

References (46)

1. Hunter T,. Signaling - 2000 and beyond. Cell 2000; 100: 113-127. (Pubitemid 30046300)
2. Kholodenko BN,. Cell-signalling dynamics in time and space. Nat Rev Mol Cell Biol 2006; 7: 165-176.
3. McConkey DJ, Orrenius S,. Signal transduction pathways in apoptosis. Stem Cells 1996; 14: 619-631. (Pubitemid 26404614)
4. Huang X, Zhang X, Farahvash B, Olumi AF,. Novel targeted pro-apoptotic agents for the treatment of prostate cancer. J Urol 2007; 178: 1846-1854. (Pubitemid 47538573)
5. Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A,. TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev 2009; 35: 280-288.
6. Grassme H, Jendrossek V, Gulbins E,. Molecular mechanisms of bacteria induced apoptosis. Apoptosis 2001; 6: 441-445. (Pubitemid 33078754)
7. Lu ML, Sato M, Cao B, Richie JP,. UV irradiation-induced apoptosis leads to activation of a 36-kDa myelin basic protein kinase in HL-60 cells. Proc Natl Acad Sci USA 1996; 93: 8977-8982.
8. Ashush H, Rozenszajn LA, Blass M, Barda-Saad M, Azimov D, Radnay J, Zipori D, Rosenschein U,. Apoptosis induction of human myeloid leukemic cells by ultrasound exposure. Cancer Res 2000; 60: 1014-1020. (Pubitemid 30129539)
9. Lagneaux L, de Meulenaer EC, Delforge A, Dejeneffe M, Massy M, Moerman C, Hannecart B, Canivet Y, Lepeltier MF, Bron D,. Ultrasonic low-energy treatment: A novel approach to induce apoptosis in human leukemic cells. Exp Hematol 2002; 30: 1293-1301. (Pubitemid 35287582)
10. Hudis CA,. Trastuzumab - Mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51. (Pubitemid 47026733)
11. Ranson M, Wardell S,. Gefitinib, a novel, orally administered agent for the treatment of cancer. J Clin Pharm Ther 2004; 29: 95-103. (Pubitemid 38482474)
12. Miller DL, Dou C,. Induction of apoptosis in sonoporation and ultrasonic gene transfer. Ultrasound Med Biol 2009; 35: 144-154.
13. Honda H, Zhao QL, Kondo T,. Effects of dissolved gases and an echo contrast agent on apoptosis induced by ultrasound and its mechanism via the mitochondria-caspase pathway. Ultrasound Med Biol 2002; 28: 673-682. (Pubitemid 34665425)
14. Feril LB, Jr., Kondo T, Zhao QL, Ogawa R, Tachibana K, Kudo N, Fujimoto S, Nakamura S,. Enhancement of ultrasound-induced apoptosis and cell lysis by echo-contrast agents. Ultrasound Med Biol 2003; 29: 331-337. (Pubitemid 36355855)
15. Cochran MC, Eisenbrey J, Ouma RO, Soulen M, Wheatley MA,. Doxorubicin and paclitaxel loaded microbubbles for ultrasound triggered drug delivery. Int J Pharm 2011; 414: 161-170.
16. Eisenbrey JR, Burstein OM, Kambhampati R, Forsberg F, Liu JB, Wheatley MA,. Development and optimization of a doxorubicin loaded poly(lactic acid) contrast agent for ultrasound directed drug delivery. J Control Release 2010; 143: 38-44.
17. Wheatley MA, Lathia JD, Oum KL,. Polymeric ultrasound contrast agents targeted to integrins: Importance of process methods and surface density of ligands. Biomacromolecules 2007; 8: 516-522. (Pubitemid 46323268)
18. Eisenbrey JR, Soulen MC, Wheatley MA,. Delivery of encapsulated Doxorubicin by ultrasound-mediated size reduction of drug-loaded polymer contrast agents. IEEE Trans Biomed Eng 2010; 57: 24-28.
19. Cochran MC, Eisenbrey JR, Soulen MC, Schultz SM, Ouma RO, White SB, Furth EE, Wheatley MA,. Disposition of ultrasound sensitive polymeric drug carrier in a rat hepatocellular carcinoma model. Acad Radiol 2011; 18: 1341-1348.
20. Kruyt FA,. TRAIL and cancer therapy. Cancer Lett 2008; 263: 14-25.
21. Ashkenazi A, Dixit VM,. Death receptors: Signaling and modulation. Science 1998; 281: 1305-1308. (Pubitemid 28406815)
22. French LE, Tschopp J,. The TRAIL to selective tumor death. Nat Med 1999; 5: 146-147. (Pubitemid 29068515)
23. Wu J, Nyborg WL,. Ultrasound, cavitation bubbles and their interaction with cells. Adv Drug Deliv Rev 2008; 60: 1103-1116.
24. Arizono Y, Yoshikawa H, Naganuma H, Hamada Y, Nakajima Y, Tasaka K,. A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents. Br J Cancer 2003; 88: 298-306. (Pubitemid 36255851)
25. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P,. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 2000; 482: 193-199.
26. Brooks AD, Ramirez T, Toh U, Onksen J, Elliott PJ, Murphy WJ, Sayers TJ,. The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis. Ann N Y Acad Sci 2005; 1059: 160-167. (Pubitemid 43211618)
27. Conticello C, Adamo L, Giuffrida R, Vicari L, Zeuner A, Eramo A, Anastasi G, Memeo L, Giuffrida D, Iannolo G,. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J Clin Endocrinol Metab 2007; 92: 1938-1942. (Pubitemid 46997213)
28. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A, Kraft AS,. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003; 22: 4953-4963. (Pubitemid 37026394)
29. Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ,. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 2005; 65: 4902-4908. (Pubitemid 40740830)
30. Luster TA, Carrell JA, McCormick K, Sun D, Humphreys R,. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol Cancer Ther 2009; 8: 292-302.
31. Siervo-Sassi RR, Marrangoni AM, Feng X, Naoumova N, Winans M, Edwards RP, Lokshin A,. Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett 2003; 190: 61-72. (Pubitemid 36106557)
32. Aroui S, Brahim S, Hamelin J, De Waard M, Breard J, Kenani A,. Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis. Apoptosis 2009; 14: 1352-1365.
33. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC,. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6: 564-567. (Pubitemid 30305907)
34. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P,. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383-385.
35. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP,. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7: 954-960. (Pubitemid 32756434)
36. Bevis KS, McNally LR, Sellers JC, Della Manna D, Londono Joshi A, Amm H, Straughn JM, Jr., Buchsbaum DJ,. Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. Gynecol Oncol 2011; 121: 193-199.
37. Wheatley MA, Forsberg F, Oum K, Ro R, El-Sherif D,. Comparison of in vitro and in vivo acoustic response of a novel 50:50 PLGA contrast agent. Ultrasonics 2006; 44: 360-367. (Pubitemid 44527958)
38. Martin FJ, Papahadjopoulos D,. Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J Biol Chem 1982; 257: 286-288. (Pubitemid 12109779)
39. Chapman IV, MacNally NA, Tucker S,. Ultrasound-induced changes in rates of influx and efflux of potassium ions in rat thymocytes in vitro. Ultrasound Med Biol 1980; 6: 47-58. (Pubitemid 10128817)
40. Dayton PA, Morgan KE, Klibanov AL, Brandenburger GH, Ferrara KW,. Optical and acoustical observations of the effects of ultrasound on contrast agents. IEEE Trans Ultrason Ferroelectr Freq Control 1999; 46: 220-232.
41. Forsberg F, Lathia JD, Merton DA, Liu JB, Le NT, Goldberg BB, Wheatley MA,. Effect of shell type on the in vivo backscatter from polymer-encapsulated microbubbles. Ultrasound Med Biol 2004; 30: 1281-1287. (Pubitemid 39576179)
42. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF,. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983; 43: 5379-5389. (Pubitemid 14230154)
43. Ahonen M, Poukkula M, Baker AH, Kashiwagi M, Nagase H, Eriksson JE, Kahari VM,. Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene 2003; 22: 2121-2134. (Pubitemid 36539562)
44. Lane D, Cote M, Grondin R, Couture MC, Piche A,. Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3. Mol Cancer Ther 2006; 5: 509-521.
45. Kim Y, Suh N, Sporn M, Reed JC,. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002; 277: 22320-22329. (Pubitemid 34967199)
46. Routes JM, Ryan S, Clase A, Miura T, Kuhl A, Potter TA, Cook JL,. Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL). J Immunol 2000; 165: 4522-4527.